DOSE FINDING PROSPECTIVE ANALYSIS AFTER HEART SURGERY for Sucrosomial Iron
Launched by CARDIOCHIRURGIA E.H. · Jun 17, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different amounts of a special type of iron supplement called Sucrosomial Iron might help people recover faster after heart surgery. The researchers want to find out if taking more iron after leaving the hospital and going to a rehabilitation center can improve recovery for patients who have anemia, which means they have low levels of red blood cells or hemoglobin.
People who might be able to join this study are adults of any gender who have had heart surgery, have anemia (with hemoglobin levels below 11), and are being discharged to a rehab facility. Participants will be randomly assigned to take different doses of the iron supplement for one month. This trial has not started enrolling patients yet. If you or a loved one fits these criteria, this study could offer a chance to see if iron supplements help speed up recovery after heart surgery.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Hb\<11; Having had Heart Surgery, Being Discharged to Rehab
- • -
- Exclusion Criteria:
- • Hb\>11.1, hematological primary disesases
About Cardiochirurgia E.H.
Cardiochirurgia E.H. is a leading clinical trial sponsor specializing in innovative cardiovascular interventions and surgical techniques. Committed to advancing cardiac care, the organization conducts rigorous clinical research aimed at improving patient outcomes and enhancing the safety and efficacy of cardiovascular treatments. With a team of experienced professionals and a robust network of clinical sites, Cardiochirurgia E.H. fosters collaboration between researchers, healthcare providers, and patients, ensuring the highest standards of ethical conduct and scientific integrity in all its trials. Their dedication to excellence positions them at the forefront of cardiovascular research, contributing significantly to the evolving landscape of cardiac health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Luca Paolo P Weltert, MD
Principal Investigator
European Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported